Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 19, 2020 Off

Teva Canada Secures Salbutamol Inhalers from its Global Supply Chain to Mitigate Shortage in Canadian Market

By BusinessWire

Teva Canada to be first company to import emergency supply of salbutamol inhalers – providing access to critically needed medication…

May 19, 2020 Off

Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic Basis of FSHD and Expanded Scientific Advisory Board

By BusinessWire

Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization UMONS Leading FSHD researcher Jeffrey…

May 19, 2020 Off

Massive Bio Completes SOC 2 Type 1 Certification for Its AI Enabled Oncology Technology Platforms Including Patient Centric Clinical Trial Matching and Enrollment Services

By BusinessWire

NEW YORK–(BUSINESS WIRE)–#ChildhoodCancerAwareness—Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial enrollment,…

May 19, 2020 Off

Pandion Therapeutics Appoints John S. Sundy, M.D., Ph.D., as Chief Medical Officer

By BusinessWire

– Dr. Sundy brings deep expertise in translational medicine and innovative drug development from leadership role at Gilead WATERTOWN, Mass.–(BUSINESS…

May 19, 2020 Off

Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020

By BusinessWire

CARLSBAD, Calif.–(BUSINESS WIRE)–$LCTX #AMD—Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies…

May 19, 2020 Off

Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting

By BusinessWire

58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival…

May 19, 2020 Off

Medallia Partners with Veeva Systems to Deliver Valuable Insights to Pharma Reps in Critical Sales Moments

By BusinessWire

Integrating Medallia’s Customer Experience Solution for the Global Life Sciences Industry SAN FRANCISCO–(BUSINESS WIRE)–Medallia, Inc. (NYSE: MDLA), the global leader…

Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials
May 19, 2020 Off

Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials

By BusinessWire

New application will connect sponsors and sites for better collaboration and faster study execution Veeva Clinical Network will bring together…

Biodesix Collaborates With Bio-Rad to Launch a Serology Test to Detect Coronavirus (COVID-19) Antibodies
May 19, 2020 Off

Biodesix Collaborates With Bio-Rad to Launch a Serology Test to Detect Coronavirus (COVID-19) Antibodies

By BusinessWire

Biodesix, Bio-Rad will launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.

May 19, 2020 Off

 Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship

By BusinessWire

Agreement Includes Strategic Investments from UPMC Enterprises and Merck Global Health Innovation Fund KENILWORTH, N.J. & PITTSBURGH–(BUSINESS WIRE)–$MRK #MRK—Merck (NYSE:…

Posts pagination

Previous 1 … 4,916 4,917 4,918 … 6,215 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Rare Diseases Treatment Market Analysis and Forecast 2025-2032: A $45.8 Billion Opportunity – Complex Challenges and Unprecedented Opportunities are Emerging – ResearchAndMarkets.com

December 19, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine